News

Roche said the newly developed analyzers will be marketed under Roche’s cobas brand and will include three platforms which will address a range of customer needs, from low-volume

Mymetics has provided license of its intra-nasal flu vaccine, under which Solvay has developed the vaccine until 2008 and also completed phase I trial. The results demonstrated that

The collaboration was made to develop two oncology targets involved in protein-protein interactions using Vernalis’ proprietary drug discovery platform. The research milestone allows the collaboration to be expanded

The facility is intended to target the global markets with antibody based drugs including Herceptin biosimilar. Dong-A and Japanese company, Meiji Seika Pharma signed an agreement to develop

ICT-107 is a dendritic cell-based vaccine which targets multiple tumor associated antigens for glioblastoma, for its Phase II clinical trial. Under the agreement, PCT will transfer and qualify

Syngas is the key precursor for the production of oxo intermediates and oxo derivatives, which are used in pharmaceutical products. The manufacturing facility develops oxo chemicals, synthetic fatty

The US Department of Health and Human Services for the Influenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD) has offered to fund the research.

The delivery system will be based upon TriLogic drug delivery platform TRI-726 and will be licensed to Mission Pharmacal for future drug development with focus on women’s health

Silenor is used for the treatment of insomnia characterized by difficulty with sleep maintenance. According to the company, FDA provided clinical and regulatory guidance is believed to help